Anlotinib (AL3818) dihydrochloride

For research use only.

Catalog No.S8726

12 publications

Anlotinib (AL3818) dihydrochloride Chemical Structure

CAS No. 1360460-82-7

Anlotinib (AL3818) is a highly potent and selective VEGFR2 inhibitor with IC50 less than 1 nM. It has broad-spectrum antitumor potential in clinical trials. Please use saline solution rather than PBS for dilutions. PBS may cause precipitation.

Size Price Stock Quantity  
USD 147 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Anlotinib (AL3818) dihydrochloride has been cited by 12 publications

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Biological Activity

Description Anlotinib (AL3818) is a highly potent and selective VEGFR2 inhibitor with IC50 less than 1 nM. It has broad-spectrum antitumor potential in clinical trials. Please use saline solution rather than PBS for dilutions. PBS may cause precipitation.
VEGFR2 [1]
(Cell-free assay)
VEGFR3 [1]
(Cell-free assay)
c-Kit [1]
(Cell-free assay)
c-Kit [1]
(Cell-free assay)
c-Kit [1]
(Cell-free assay)
0.2 nM 0.7 nM 14.8 nM 14.8 nM 14.8 nM
In vitro

Anlotinib occupies the ATP-binding pocket of VEGFR2 tyrosine kinase and shows high selectivity and inhibitory potency (IC 50 <1 nmol/L) for VEGFR2 relative to other tyrosine kinases. Anlotinib inhibits VEGFR2 and VEGFR3 with IC50 values of 0.2 and 0.7 nmol/L, respectively. The inhibitory potency of anlotinib against VEGFR1 is lower, with an IC50 value of 26.9 nmol/L. The IC50 values of anlotinib for inhibition of the PDGFR-related kinases c-Kit and PDGFRβ are 14.8 and 115.0 nmol/L, respectively. Anlotinib has little effect on the activity of other kinases, including c-Met, c-Src, EGFR and HER2, even at a concentration of 2000 nmol/L. Anlotinib inhibits VEGF-induced signaling and cell proliferation in HUVEC with picomolar IC50 values. However, micromolar concentrations of anlotinib are required to inhibit tumor cell proliferation directly in vitro. Anlotinib significantly inhibits HUVEC migration and tube formation; it also inhibits microvessel growth from explants of rat aorta in vitro[1].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
U-87MG MkDCSpVv[3Srb36gZZN{[Xl? NFfyfWcxNjBzLDCwMlEtKDFuIEGwJIFv\CBzMECg{txO NHHnTIMyNjViaB?= M{nWTYlvcGmkaYTl[EBRTEeILVLCMZN1cW23bHH0[YQheGixc4Doc5J6dGG2aX;uJI9nKFCGR1\S{tItKEGNVDDhcoQhTVKNIHnuJHUuQDePRzDj[Yxtew>? MonCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2NE[4OVMoRjJ7NES2PFU{RC:jPh?=
Mo7e MkPYSpVv[3Srb36gZZN{[Xl? NUfxV2FZOC5yMTygNE4yNCBzLDCxNEBidmRiMUCwJO69VQ>? M1Pq[|EvPSCq MV7BcoxwfGmwaXKgbY5pcWKrdHXkJHNETuLCkEJihLB{fGmvdXzheIVlKHCqb4PwbI9zgWyjdHnvckBw\iCl4pEQT4l1NCCDS2SgZY5lKEWUSzDpckBOdzenIHPlcIx{ MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR2Nki1N{c,Ojl2NE[4OVM9N2F-
HUVEC NIjYcFhHfW6ldHnvckBie3OjeR?= NFzuPZUxNjBzLDCwMlEtKDFuIEGwJIFv\CBzMECg{txO NFzsT4QyNjViaB?= MWfhcoxwfGmwaXKgbY5pcWKrdHXkJHZGT0ckgKDzeIlufWyjdHXkJIlvfHKjY3XscJVt[XJicHjvd5Bpd3K7bHH0bY9vKG:oIG\FS2ZTOiCrbjDhJINwdmOnboTyZZRqd28kgKDk[ZBmdmSnboSge4F6KGmwIFjVWmVEKHerdHigZUB{fWKwYX7vcY9t[XJiSVO1NEB3[Wy3ZR?= MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR2Nki1N{c,Ojl2NE[4OVM9N2F-
A549 MoLBR4VtdCC4aXHibYxqfHliYYPzZZk> MWOyOEwhPDhiYX7kJFcz6oDLaB?= Mn6yTWM2OD14ND64NkDPxE4xvJj0QVI1KGkxvJm7JGlEPTB;M{CuN|Qh|ryP78{IeF01QCCq78{JP{BKSzVyPUG3MlI6KM7:Tf-8jJQ:PzJiaP-8jS=> NU\1Xo1rRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{C3OVUzPDJpPkOwO|U2OjR{PD;hQi=>
NCI-H1975 NV7xc2t2S2WubDD2bYFjcWyrdImgZZN{[Xl? NIi1R4w56oDLzsznM41t MUKyOQKBkWh? NUjKfmx7S2WubDD2bYFjcWyrdImge4F{KGSnY4LlZZNm\CC{ZX3hdoti[my7 M1XJWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyOEexOVI3Lz5|MEi3NVUzPjxxYU6=
Calu-1 NF\2e2dE\WyuII\pZYJqdGm2eTDhd5NigQ>? NWT5TJprOjRuIES4JIFv\CB5MvMAjYg> NX7PRlQ5UUN3ME22NU4zOyEQvF5vwKh1RTJ2IHlvwKk8KEmFNUC9N|YvQCEQvF5vwKh1RTR6IHlvwKk8KEmFNUC9NlgvPjRizszN89yJfD15MjDo89yK MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODd3NUK0Nkc,OzB5NUWyOFI9N2F-

... Click to View More Cell Line Experimental Data

Methods Test Index PMID
Western blot
TP53 / Cleaved-caspase 3 / Cleaved PARP ; 

PubMed: 30139768     

BCPAP (C) and 8505C (F) cells were treated with anlotinib (0, 1, 5, 10 and 15 µM) for 36 h. Cell lysates were prepared and subjected to Western blot to detect the expression of TP53, cleaved caspase 3 (CL-caspase 3) and cleaved PARP (CL-PARP).

Beclin-1 / LC3-I / LC3-II ; 

PubMed: 30755242     

Calu-1 and A549 cells were treated with anlotinib 0–20 μM for 24 h or anlotinib 20 μM for 0–24 h, and the expression levels of beclin-1 and LC3-I/II were detected by western blotting.

Akt / p-Akt / mTOR / p-mTOR ; 

PubMed: 30755242     

Expression of Akt, pAkt, mTOR, p-mTOR, and beclin-1 in lung cancer cells after treatment with concentration gradient anlotinib for 24 h was detected by immunoblotting. 

30139768 30755242
LC3-II ; 

PubMed: 30755242     

Calu-1 and A549 cells on the coverslips were treated with anlotinib or RAPA for 48 h. The punctate patterns of LC3-II were observed by confocal microscopy. 

Growth inhibition assay
Cell viability; 

PubMed: 30755242     

a, Dose-response curves of Calu-1 and A549 cells to anlotinib treatment. Cells were cultured by anlotinib at various concentrations for 24, 48 and 72 h and cell viability was detected by CCK-8 assay. b, Representative images of clone formation assay.

In vivo Anlotinib decreases vascular density in tumor tissue in vivo. Compared with the well-known tyrosine kinase inhibitor sunitinib, once-daily oral dose of anlotinib shows broader and stronger in vivo antitumor efficacy and, in some models, causes tumor regression in nude mice. It is well-tolerated in mice. Anlotinib is efficacious at doses (1.5‐6 mg/kg daily) that are significantly lower than effective doses of other TKI, which require doses of 20‐100 mg/kg to achieve significant inhibition of tumor growth in mice[1]. In vivo, anlotinib has showed broad activity against human tumor xenograft models of the colon (SW-620), ovarian (SK-OV-3), liver (SMMC-7721), renal (Caki-1), glioma (U87MG), and non-small cell lung (Calu-3) during dosing period. In Sprague-Dawley rats and beagle dogs, anlotinib is rapidly absorbed from the gastrointestinal tracks after oral administration. The oral bioavailability is 23-45 % in rats and 47-74 % in dogs. Anlotinib exhibits large volume of distribution in both species. In rats, primary tissues, such as the lung, kidneys, liver, and heart, exhibit significant higher exposure levels to anlotinib compared with that in plasma. The exposure level in the brain is comparable with the corresponding plasma level. In tumor-bearing mice, anlotinib concentrates 2.4-2.6 times in tumor tissue than in plasma. In human, anlotinib exhibits a quite long t1/2 (96 ± 17 h), which appeared to be dose-independent[2]. The terminal half-life of anlotinib in dogs (22.8±11.0 h) is longer than that in rats (5.1±1.6 h). This difference appeares to be mainly associated with an interspecies difference in total plasma clearance (rats, 5.35±1.31 L/h/kg; dogs, 0.40±0.06 L/h/kg). In human plasma, anlotinib is predominantly bound to albumin and lipoproteins, rather than to α1-acid glycoprotein or γ-globulins[3].


Kinase Assay:


- Collapse

Enzyme-linked immunosorbent assay:

Inhibitory activity of anlotinib against tyrosine kinases was determined using ELISA. Reaction of ATP with tyrosine kinase was initiated in reaction buffer (50 mmol/L HEPES pH 7.4, 50 mmol/L MgCl2, 0.5 mmol/L MnCl2, 0.2 mmol/L Na3VO4, 1 mmol/L DTT) and incubated for 1 hour at 37°C in 96-well plates precoated with 20 μg/mL Poly(Glu,Tyr)4:1. The plate was incubated with PY99 antibody and then with HRP-conjugated anti-mouse IgG. After reaction with o-phenylenediamine solution and then termination with the addition of 2N H2SO4, absorbance was measured at 490 nm using a Synergy H4 Hybrid reader.
Cell Research:


- Collapse
  • Cell lines: HUVEC, Mo7e, U-87MG and A431 cells
  • Concentrations: 0-10 μM
  • Incubation Time: 1.5 h
  • Method:

    Serum-starved HUVEC, Mo7e, U-87MG and A431 cells are treated with different concentrations of test agents for 1.5 h and then stimulated with vascular endothelial growth factor (VEGF; 20 ng/mL), stem cell factor-1 (SCF-1; 2.5 ng/mL), platelet-derived growth factor-BB (PDGF-BB; 10 ng/mL), or epidermal growth factor (EGF; 10 ng/mL) for 10 min, respectively. Cell lysates are probed with the indicated antibodies.

    (Only for Reference)
Animal Research:


- Collapse
  • Animal Models: human colon cancer SW620 xenograft model(Balb/cA-nude mice, 5-6 weeks old)
  • Dosages: 0.75, 1.5, 3 and 6 mg/kg
  • Administration: oral
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 96 mg/mL (199.85 mM)
Water 96 mg/mL (199.85 mM)
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 480.36


CAS No. 1360460-82-7
Storage powder
in solvent
Synonyms N/A
Smiles CC1=CC2=C(N1)C=CC(=C2F)OC3=C4C=C(C(=CC4=NC=C3)OCC5(CC5)N)OC.Cl.Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02825563 Completed Drug: Anlotinib Advanced Cancer Chia Tai Tianqing Pharmaceutical Group Co. Ltd. June 2016 Phase 1
NCT02752516 Unknown status Drug: Anlotinib Cancer Chia Tai Tianqing Pharmaceutical Group Co. Ltd. April 27 2016 Phase 1
NCT02622932 Completed Drug: Anlotinib and 14C-labeled Anlotinib Advanced Solid Tumors Chia Tai Tianqing Pharmaceutical Group Co. Ltd. December 2 2015 Phase 1
NCT02584478 Recruiting Drug: AL3818|Drug: Carboplatin|Drug: Paclitaxel Endometrial Carcinoma|Ovarian Carcinoma|Fallopian Tube Carcinoma|Primary Peritoneal Carcinoma|Cervical Carcinoma Advenchen Laboratories LLC December 2015 Phase 1|Phase 2
NCT02558348 Terminated Drug: AL3818 Endometrial Cancer|Ovarian Cancer|Cervical Cancer Advenchen Laboratories LLC November 2015 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

VEGFR Signaling Pathway Map

Related VEGFR Products

Tags: buy Anlotinib (AL3818) dihydrochloride | Anlotinib (AL3818) dihydrochloride supplier | purchase Anlotinib (AL3818) dihydrochloride | Anlotinib (AL3818) dihydrochloride cost | Anlotinib (AL3818) dihydrochloride manufacturer | order Anlotinib (AL3818) dihydrochloride | Anlotinib (AL3818) dihydrochloride distributor
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID